Compare · ABT vs ASND
ABT vs ASND
Side-by-side comparison of Abbott Laboratories (ABT) and Ascendis Pharma A/S (ASND): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ASND operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $152.98B, about 10.8x ASND ($14.13B).
- Over the past year, ABT is down 32.1% and ASND is up 35.9% - ASND leads by 68.0 points.
- ASND has been more active in the news (11 items in the past 4 weeks vs 5 for ABT).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- Ascendis Pharma A/S
- Price
- $90.48+3.09%
- $238.77+4.68%
- Market cap
- $152.98B
- $14.13B
- 1M return
- +3.10%
- -3.51%
- 1Y return
- -32.07%
- +35.88%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 5
- 11
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Latest ABT
- Director Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)
- SEC Form 11-K filed by Abbott Laboratories
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
Latest ASND
- SEC Form 6-K filed by Ascendis Pharma A/S
- SEC Form 6-K filed by Ascendis Pharma A/S
- Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
- SEC Form 6-K filed by Ascendis Pharma A/S
- 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
- SEC Form 6-K filed by Ascendis Pharma A/S
- Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
- EVP & Chief Financial Officer Smith Scott Thomas bought $21,900 worth of Ordinary Shares (100 units at $219.00), increasing direct ownership by 2% to 4,367 units (SEC Form 4)
- Director Bienaime Jean Jacques bought $111,562 worth of Ordinary Shares (500 units at $223.12), increasing direct ownership by 125% to 900 units (SEC Form 4)
- EVP & Chief Financial Officer Smith Scott Thomas bought $55,830 worth of Ordinary Shares (250 units at $223.32), increasing direct ownership by 6% to 4,267 units (SEC Form 4)